decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
Medicare_Carriers_Manual / 2049 / 2049.1_Definitionof_Drug_or_Biological.--
Subscribe or sign in to view the full article.
Article Overview
This premium article covers the Medicare Carriers Manual discussion of how drugs and biologicals are evaluated for statutory and program eligibility purposes. It is relevant to coders, billing staff, compliance teams, and reimbursement professionals who need to understand the general documentation and reference-source context behind these determinations. The article focuses on the governing definition, the role of recognized drug references and hospital committee approval, and why inclusion in a reference source alone is not sufficient.
Why This Topic Matters
Accurate classification of drugs and biologicals affects coverage, billing, and compliance under Medicare policy. Understanding the governing framework helps organizations avoid relying on incomplete criteria when evaluating whether a product meets program requirements.
What You Will Learn
- The Medicare framework used to evaluate whether a product may qualify as a drug or biological
- The role of recognized pharmacopoeias and hospital committee approval in that evaluation
- Why reference inclusion alone does not establish program eligibility
- How this policy context supports compliant billing and documentation practices
Who Should Read This
- Medical coders
- Billing specialists
- Compliance professionals
- Reimbursement analysts
- Hospital pharmacy staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com